NCT07252661
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Not Yet Recruiting · Phase 1 · AccSalus Biosciences, Inc. · registry updated 2026-10-28
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread. The purpose of this Phase 1 clinical trial is to find a safe dose of ACC-1898 and to understand how the body absorbs, distributes, and eliminates the drug (pharmacokinetics / PK). The study will also look for early signs that ACC-1898 may slow or shrink tumors and explore possible biological markers related to drug activity. Adults with advanced or metastatic solid tumors who have no remaining standard treatment options may take part. All participants will receive ACC-1898 tablets by mouth once daily in repeating 21-day cycles. Treatment may continue for up to two years if the cancer does not worsen and side effects are manageable. Safety information, laboratory results and imaging scans (CT or MRI) will be collected regularly. The study will first test different dose levels (dose-escalation phase) and may later expand enrollment in selected tumor types once a recommended dose is found.
Inclusion
- Inclusion Criteria (highlights):
- Adults (≥ 18 years) with histologically confirmed advanced or metastatic solid tumors that have progressed after standard therapy or for which no effective standard option exists.
- At least one measurable lesion per RECIST v1.1.
- ECOG (Eastern Cooperative Oncology Group) Performance Status 0-1 (2 may be allowed with Medical Monitor approval).
- Resolved acute effects from prior therapy to ≤ Grade 1 per CTCAE v5.0.
- Adequate organ function (hematologic, hepatic, renal).
Exclusion
- Exclusion Criteria (highlights):
- Known primary CNS (central nervous system) malignancy or symptomatic brain metastases requiring supraphysiologic steroids (unless stable ≥ 3 months after therapy).
- Active or uncontrolled infection (including HBV, HCV, HIV) not meeting protocol control criteria.
- HBV: Hepatitis B Virus HCV: Hepatitis C Virus HIV: Human Immunodeficiency Virus
- Significant GI disease that could impair oral drug absorption (e.g., unresolved Grade \> 1 nausea/diarrhea).
- Active liver or biliary disease (except stable metastases or Gilbert's syndrome).